Every material Form 8-K SUTRO BIOPHARMA, INC. has filed with the SEC since March 23, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sutro Biopharma reported second quarter 2026 revenue of $9.8 million, down from $63.7 million a year earlier, and a net loss of $38.5 million, or $2.33 per share, versus a net loss of $11.5 million, or $1.35 per share, a year earlier. The company also reported $164.3 million in cash, cash equivalents and marketable securities as of June 30, 2026, which it says supports operations into at least the second quarter of 2028.
Q2 2026 revenue was $9.8 million, mainly from the Astellas collaboration, compared with $63.7 million in Q2 2025.
Net loss was $38.5 million, or $2.33 per share, compared with $11.5 million, or $1.35 per share, in Q2 2025.
Cash, cash equivalents and marketable securities were $164.3 million, down from $202.6 million as of March 31, 2026.
Total R&D and G&A expenses were $39.5 million, down from $48.7 million a year earlier.
Sutro Biopharma reported first quarter 2026 results, with revenue of $14.5 million, down from $17.4 million a year earlier, and a net loss of $38.5 million, down from $76.0 million. Net loss per share was $2.94 versus $9.08, and cash, cash equivalents and marketable securities rose to $202.6 million from $141.4 million at December 31, 2025, which the company says supports operations into at least the second quarter of 2028.
Revenue was $14.5 million for the quarter, versus $17.4 million in the first quarter of 2025, principally related to the Astellas collaboration.
Net loss was $38.5 million, or $2.94 per share, versus $76.0 million, or $9.08 per share, a year earlier.
Underwritten offering of 7,868,383 shares at $13.98 per share, with gross proceeds of $110.0 million before underwriting discounts and expenses.
The luvelta program has been closed, with no additional investment planned.
Sutro Biopharma reported full-year 2025 results in a press release furnished with an 8-K on March 23, 2026. Revenue rose to $102.5 million from $62.0 million and net loss narrowed to $191.1 million from $227.5 million, but the company also recorded $53.4 million in restructuring and related costs. The company also terminated its at-the-market share sales agreement with Jefferies LLC effective March 23, 2026, so it can no longer sell common shares under that program.
Revenue was $102.5 million for 2025, up from $62.0 million in 2024, mainly tied to Astellas and Ipsen collaborations.
Net loss was $191.1 million, or $22.49 per share, versus $227.5 million, or $29.40 per share, in 2024.
Restructuring and related costs were $53.4 million in 2025, compared with none in 2024.
Cash, cash equivalents and marketable securities were $141.4 million at December 31, 2025, versus $316.9 million a year earlier.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every SUTRO BIOPHARMA, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →